OABI OmniAb, Inc.
Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 1846253 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY90.6%
TTM net income YoY31.7%
TTM EPS YoY42.4%
Revenue 3-yr CAGR-14.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-115.9%
Net margin-108.1%
FCF margin5.9%
EBITDA margin-64.2%
Returns
ROE-16.5%
ROA-14.5%
ROIC (approx.)-15.5%
Asset turnover0.13x
Leverage & solvency
Liabilities / assets14.4%
Debt / equity0.00x
Current ratio4.21x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.06x
Accruals ratio-15.4%
Payout ratio—
Capex / revenue0.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $3.99M | $13.41M | $14.43M | $8.38M | $2.24M | $3.90M | $4.15M | $10.80M |
| R&D expense | $9.55M | $9.59M | $9.64M | $13.91M | $10.38M | $10.86M | $12.60M | $13.31M |
| SG&A expense | $7.24M | $6.65M | $6.62M | $6.84M | $6.78M | $7.68M | $7.92M | $7.36M |
| Operating income | -$16.37M | -$6.64M | -$7.83M | -$15.77M | -$18.14M | -$16.22M | -$18.84M | -$15.88M |
| Pretax income | -$15.86M | -$6.21M | -$7.26M | -$14.55M | -$17.69M | -$15.76M | -$18.31M | -$15.22M |
| Income tax | -$127,000 | -$353,000 | $442,000 | -$367,000 | -$1.16M | $119,000 | -$106,000 | -$2.15M |
| Net income | -$15.73M | -$5.86M | -$7.71M | -$14.18M | -$16.52M | -$15.88M | -$18.20M | -$13.07M |
| EBITDA | -$15.87M | -$6.04M | -$7.22M | $3.30M | -$17.24M | -$15.42M | -$17.88M | -$8.27M |
| EPS (basic) | -0.12 | -0.05 | -0.06 | — | -0.14 | -0.15 | -0.17 | — |
| EPS (diluted) | -0.12 | -0.05 | -0.06 | — | -0.14 | -0.15 | -0.17 | — |
| Weighted avg. shares (diluted) | 129.29M | 128.79M | 128.25M | — | 114.73M | 106.15M | 105.62M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $22.88M | $24.34M | $29.05M | $25.52M | $29.10M | $18.84M | $11.45M | $28.16M |
| Short-term investments | $41.33M | $27.66M | $20.03M | $28.50M | $30.96M | $23.33M | $32.70M | $31.84M |
| Receivables | $2.57M | $10.33M | $12.64M | $7.39M | $3.10M | $2.71M | $6.48M | $5.27M |
| Inventory | $1.07M | $1.01M | $920,000 | $823,000 | $443,000 | $316,000 | — | $48,000 |
| Current assets | $70.98M | $66.01M | $65.12M | $65.34M | $66.35M | $47.62M | $53.58M | $68.14M |
| PP&E, net | $7.94M | $8.47M | $9.02M | $9.43M | $13.28M | $14.06M | $14.71M | $15.49M |
| Goodwill | $83.98M | $83.98M | $83.98M | $83.98M | $83.98M | $83.98M | $83.98M | $83.98M |
| Intangibles | $113.02M | $116.07M | $119.12M | $125.15M | $128.38M | $131.60M | $134.83M | $138.06M |
| Total assets | $290.92M | $290.26M | $293.65M | $300.91M | $309.69M | $295.67M | $306.18M | $325.56M |
| Current liabilities | $16.85M | $13.76M | $13.57M | $16.25M | $13.28M | $12.64M | $11.41M | $15.09M |
| Total liabilities | $41.76M | $29.98M | $31.00M | $33.89M | $32.25M | $33.61M | $32.67M | $37.94M |
| Shareholders' equity | $249.16M | $260.27M | $262.65M | $267.03M | $277.44M | $262.06M | $273.52M | $287.62M |
| Shares outstanding | 145.86M | 145.39M | 144.78M | 144.31M | 143.96M | 122.70M | 122.13M | 121.60M |
| Cash flow statement | ||||||||
| Operating cash flow | $10.57M | $2.68M | -$4.91M | -$5.67M | -$9.76M | -$5.15M | -$15.87M | -$3.87M |
| Capital expenditure | $0 | $110,000 | $167,000 | $9,000 | $182,000 | $165,000 | $209,000 | $46,000 |
| Free cash flow | $10.57M | $2.57M | -$5.08M | -$5.68M | -$9.95M | -$5.31M | -$16.08M | -$3.92M |
| Investing cash flow | -$13.49M | -$7.62M | $8.44M | $2.71M | -$7.67M | $12.30M | -$878,000 | $385,000 |
| Financing cash flow | $1.46M | $233,000 | $0 | -$50,000 | $27.68M | $236,000 | $44,000 | $3.85M |
| Depreciation & amortization | $500,000 | $600,000 | $606,000 | $19.06M | $900,000 | $800,000 | $966,000 | $7.61M |
| Stock-based compensation | $3.06M | $3.16M | $3.34M | $3.61M | $3.96M | $4.11M | $4.14M | $5.12M |
Free plan shows the latest 8 periods; Pro shows all 21 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.